Calyxo vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calyxo is a urology medical device company developing CVAC, a vacuum-assisted catheter for kidney stone fragment retrieval; raised $80M Series C in 2023;
About
Calyxo is a medical device company founded in 2017 and headquartered in Pleasanton, California, focused on improving outcomes in kidney stone treatment. The company's lead product is the CVAC System (Calyxo Vacuum-Assisted Catheter), an FDA-cleared ureteroscopy tool that uses suction to vacuum out kidney stone fragments during a single minimally invasive procedure. Traditional stone removal with a basket retrieval device requires multiple passes and often leaves residual fragments — a problem Calyxo's system addresses by continuously aspirating debris as the laser breaks up stones, achieving substantially higher stone-free rates in a single operating room session.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.